Genzyme Surgical Products
This article was originally published in The Gray Sheet
Executive SummaryCardiovascular and general surgical biomaterials business receives 510(k) clearance to market the Sepramesh hyaluron-based biosurgical composite for hernia repairs, the company announces March 22. Sepramesh contains a bioresorbable barrier to prevent adhesions common among traditional mesh products. Genzyme plans a roll-out in the second quarter of 2000 targeting the estimated $25 mil. market opportunity among the 64,000 annual U.S. incisional hernia repair procedures
You may also be interested in...
New medicines under evaluation at the European Medicines Agency.
Discussions on the shape of health care have moved from “reimagining” to the next stage: building and executing on the vision. That is the thrust of EY’s NextWave Report: New Horizons 2019. Additionally, for medtechs seeking business continuum, “duality” is now a preoccupying thought.
The idea that public corporations have obligations that extend beyond the fiduciary responsibility to shareholders will be the dominant measure of responsible business behavior in the coming decade. Uncertainty about the extent of these commitments – commonly referenced as the environmental, social and governance (ESG) agenda – has produced equally variable responses from companies in the health care business.